This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and to highlight opportunities ...

The goal of this collaborative is to examine and highlight the bottlenecks to drug research and development (R&D) for highly prevalent chronic diseases and develop a set of key considerations and ...

Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity.

A new AI platform offers free drug discovery tools to global health researchers, aiming to speed up treatments for malaria, ...

A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In a move that could dramatically reshape the landscape for rare ...

Massimo Radaelli, PhD, is a European pharmaceutical industry leader and entrepreneur who has devoted more than 30 years to the innovation of therapies to treat rare diseases. He is President and CEO ...

Growing evidence shows that gut microbes are closely linked to a broad range of diseases, creating new room for ...

Against this backdrop, Sanyou Bio, in partnership with Tongxieyi, jointly hosted the "2026 China New Drug Source Innovation Forum" on February 8, 2026, in Shanghai. The forum bought together visionary ...

Your editorial on “Why Vinay Prasad Had to Go at FDA” should be a wake-up call for anyone who cares whether federal bureaucrats get to decide if promising new medicines are available to desperately ...

Professors Elaine Bignell and Neil A.R. Gow address the threat of fungal infections, highlighting the sharp rise in ...

The drug and biotech sector has been in a recovery mode since mid-2025, after going through a difficult period between 2021 ...